AstraZeneca heart drug wins approval in China
LONDON (Reuters) - AstraZeneca has won approval for its new heart drug Brilinta in China, an increasingly important market for the British pharmaceuticals group.
China's State Food and Drug Administration has issued an drug import license for the product, meaning it will now be available for treating patients with acute coronary syndrome in the country, the company said on Thursday.
Brilinta has proved better than the cheaper generic medicine clopidogrel in preventing the recurrence of heart attacks, but its sales to date in markets around the world have been disappointing.
Revitalizing the product is an early priority for new Chief Executive Pascal Soriot, who said last month that Brilinta could do "far better".
(Reporting by Ben Hirschler; Editing by Helen Massy-Beresford)
- U.S.'s Kerry expresses regret to India over diplomat case |
- Mega Millions winners in Georgia, California to split $648 million |
- China confirms near miss with U.S. ship in South China Sea
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- Fed cuts bond buying in first step away from historic stimulus |
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow